Laglidadg homing endonuclease variants having mutations in two functional subdominants und use thereof

(19)

(11)

EP 2 343 368 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	26.10.2011 Bulletin 2011/43

(43)	Date of publication:
	13.07.2011 Bulletin 2011/28

(21)	Application number: 10012259.7

(22)	Date of filing: 03.10.2006

(27)	Previously filed application: 03.10.2006 PCT/IB20/06003893

(51)

International Patent Classification (IPC):

C12N 9/22^(2006.01)
C12N 15/64^(2006.01)
C12N 15/79^(2006.01)

C12N 15/55^(2006.01)
C12N 15/10^(2006.01)
C12N 15/82^(2006.01)

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA HR MK RS

(30)

Priority:

25.10.2005 WO PCT/IB2005/003568

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	06842331.8 / 1979478

(71)	Applicant: Cellectis
	93235 Romainville Cedex (FR)

(72)	Inventor:
	Paques, Frédéric 92340 Bourg-La-Reine (FR)

(74)	Representative: Noel, Chantal Odile et al
	Cabinet Orès 36, rue de St Pétersbourg 75008 Paris 75008 Paris (FR)


	Remarks:
	Claims filed after the date of filing of the application (Rule 68(4) EPC).


	Remarks:
	This application was filed on 30-09-2010 as a divisional application to the application mentioned under INID code 62.

(54)	Laglidadg homing endonuclease variants having mutations in two functional subdominants und use thereof

(57) A LAGLIDADG homing endonuclease variant, having mutations in two separate subdomains, each binding a distinct part of a modified DNA target half-site, said LAGLIDADG homing endonuclease variant being able to cleave a chimeric DNA target sequence comprising the nucleotides bound by each subdomain.
Use of said herodimeric meganuclease and derived products for genetic engineering, genome therapy and antiviral therapy.